Dan Riskin is an American entrepreneur and surgeon.[1] As an expert in healthcare artificial intelligence, Riskin has promoted healthcare quality improvement and helped shape policy in the US and globally.[2][3] Riskin's companies, featured in Forbes and The Wall Street Journal, have influenced the care of millions of patients.[4] He continues to practice, teach, and perform research as Clinical Professor of Surgery at Stanford University.[5]
Riskin grew up in Los Angeles, California. He began writing software at age 5, selling software at age 12, and winning regional awards in software programming during grammar school.[6] At age 15, Riskin received the Bausch and Lomb Outstanding Scientist Award. He began college at age 16 as a Regent’s Scholar at University of California.[7] He holds a MD, four board certifications, and a MBA with a focus in bioinformatics.
Business
While a student at MIT and Stanford, Riskin designed a painless wound closure device for which he was issued US patents and FDA approval.[8] The product has been used successfully on hundreds of thousands of patients.[9] Riskin cofounded Wadsworth Medical Technologies, which was acquired by DQ Holdings.[10]
In 2011, Riskin founded and became CEO of Health Fidelity, a health AI company which measures clinical quality and risk based on routinely collected data. The product has influenced the care of tens of millions of patients. It was acquired by Edifecs in a transaction valued in excess of $150 million.[11]
In 2015, Riskin founded and became CEO of Verantos, a health AI company which determines preferred treatment for an individual based on clinical experience across millions of patients. Verantos is the leader in high-validity real-world evidence, naming top life sciences firms as customers and contracted by the FDA for data quality.[12] The company was recognized as Bioinformatics Company of the Year in 2021 and was subsequently recognized by Inc 5000 and Deloitte Fast 500 as one of America's fastest growing private companies.
Policy and public service
Riskin has advocated a bipartisan approach to leverage clinical data to improve US healthcare quality. He described two decades of health data reform. The first, from 2010 - 2020, would institute electronic data capture and enable value-based healthcare. The second decade, from 2020 - 2030, would leverage the massive amounts of collected data to tailor therapy and enable personalized medicine.
Focusing on the first decade of healthcare data reform, capturing electronic information and improving value-based workflow, Riskin promoted a transition to electronic health records and use of data to improve care as an advisor to multiple administrations. These efforts were enacted through the HITECH Act in 2009 and Affordable Care Act in 2010. Riskin's academic work "Re-examining health IT policy: What will it take to derive value from our investment?" encouraged national discussion on innovation and analytics.[13] He founded and built a company, Health Fidelity, with a vision to capture accurate electronic information and improve value-based workflow.[14]
Focusing on the second decade of healthcare data reform, tailoring therapy based on real world evidence, Riskin provided Congressional testimony in the 21st Century Cures Initiative in 2014.[15] He met in Congressional retreat to help refine the bill in 2015.[16] The 21st Century Cures Act, passed in December 2016, included a pathway to incorporate real-world evidence into regulatory decision-making. Riskin's academic work describes an approach to use advanced technology and data to enable credible real-world evidence.[17][18][19] He founded and built a company, Verantos, with a vision to refine the standard of care based on real-world evidence.[20]
Riskin has continued to focus national attention on healthcare quality through the HHS Quality Measurement Task Force,[21] in Centers for Medicare and Medicaid Services Grand Rounds,[22] in FDA Grand Rounds and workshops,[23] as a Congressionally-appointed member of the US Health IT Advisory Committee,[24] and through academic publication.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
